Literature DB >> 19351838

Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Hiroaki Wakimoto1, Santosh Kesari, Christopher J Farrell, William T Curry, Cecile Zaupa, Manish Aghi, Toshihiko Kuroda, Anat Stemmer-Rachamimov, Khalid Shah, Ta-Chiang Liu, Deva S Jeyaretna, Jason Debasitis, Jan Pruszak, Robert L Martuza, Samuel D Rabkin.   

Abstract

Glioblastoma, the most malignant type of primary brain tumor, is one of the solid cancers where cancer stem cells have been isolated, and studies have suggested resistance of those cells to chemotherapy and radiotherapy. Here, we report the establishment of CSC-enriched cultures derived from human glioblastoma specimens. They grew as neurospheres in serum-free medium with epidermal growth factor and fibroblast growth factor 2, varied in the level of CD133 expression and very efficiently formed highly invasive and/or vascular tumors upon intracerebral implantation into immunodeficient mice. As a novel therapeutic strategy for glioblastoma-derived cancer stem-like cells (GBM-SC), we have tested oncolytic herpes simplex virus (oHSV) vectors. We show that although ICP6 (UL39)-deleted mutants kill GBM-SCs as efficiently as wild-type HSV, the deletion of gamma34.5 significantly attenuated the vectors due to poor replication. However, this was significantly reversed by the additional deletion of alpha47. Infection with oHSV G47Delta (ICP6(-), gamma34.5(-), alpha47(-)) not only killed GBM-SCs but also inhibited their self-renewal as evidenced by the inability of viable cells to form secondary tumor spheres. Importantly, despite the highly invasive nature of the intracerebral tumors generated by GBM-SCs, intratumoral injection of G47Delta significantly prolonged survival. These results for the first time show the efficacy of oHSV against human GBM-SCs, and correlate this cytotoxic property with specific oHSV mutations. This is important for designing new oHSV vectors and clinical trials. Moreover, the new glioma models described in this study provide powerful tools for testing experimental therapeutics and studying invasion and angiogenesis.

Entities:  

Mesh:

Year:  2009        PMID: 19351838      PMCID: PMC2785462          DOI: 10.1158/0008-5472.CAN-08-3886

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

2.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

3.  Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.

Authors:  Alfred T Ogden; Allen E Waziri; Richard A Lochhead; David Fusco; Kim Lopez; Jason A Ellis; Joann Kang; Marcela Assanah; Guy M McKhann; Michael B Sisti; Paul C McCormick; Peter Canoll; Jeffrey N Bruce
Journal:  Neurosurgery       Date:  2008-02       Impact factor: 4.654

4.  Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria.

Authors:  H S Günther; N O Schmidt; H S Phillips; D Kemming; S Kharbanda; R Soriano; Z Modrusan; H Meissner; M Westphal; K Lamszus
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

5.  Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.

Authors:  Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Joshua Shroll; Michal Nowicki; Akihiro Otsuki; E Antonio Chiocca; Balveen Kaur
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

6.  Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons.

Authors:  Sunghoi Hong; Un Jung Kang; Ole Isacson; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2007-10-18       Impact factor: 5.372

7.  Temozolomide preferentially depletes cancer stem cells in glioblastoma.

Authors:  Dagmar Beier; Stefanie Röhrl; Deepu R Pillai; Stefanie Schwarz; Leoni A Kunz-Schughart; Petra Leukel; Martin Proescholdt; Alexander Brawanski; Ulrich Bogdahn; Ariane Trampe-Kieslich; Bernd Giebel; Jörg Wischhusen; Guido Reifenberger; Peter Hau; Christoph P Beier
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

8.  Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.

Authors:  Peter C Huszthy; Dorota Goplen; Frits Thorsen; Heike Immervoll; Jian Wang; Anja Gutermann; Hrvoje Miletic; Rolf Bjerkvig
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

Review 9.  Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.

Authors:  Lee A Selznick; Mohammed F Shamji; Peter Fecci; Matthias Gromeier; Allan H Friedman; John Sampson
Journal:  Neurosurg Rev       Date:  2008-02-08       Impact factor: 3.042

10.  Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.

Authors:  Minna Eriksson; Kilian Guse; Gerd Bauerschmitz; Pekka Virkkunen; Maija Tarkkanen; Minna Tanner; Tanja Hakkarainen; Anna Kanerva; Renee A Desmond; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2007-09-11       Impact factor: 11.454

View more
  202 in total

1.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

Review 3.  Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Authors:  Ryuichi Kanai; Hiroaki Wakimoto; Tooba Cheema; Samuel D Rabkin
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Functional drug screening assay reveals potential glioma therapeutics.

Authors:  Christian E Badr; Thomas Wurdinger; Bakhos A Tannous
Journal:  Assay Drug Dev Technol       Date:  2010-12-27       Impact factor: 1.738

Review 5.  Neural stem cell therapy for cancer.

Authors:  Juli Rodriguez Bagó; Kevin T Sheets; Shawn D Hingtgen
Journal:  Methods       Date:  2015-08-24       Impact factor: 3.608

6.  A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Authors:  Fares Nigim; Shin-Ichi Esaki; Michael Hood; Nina Lelic; Marianne F James; Vijaya Ramesh; Anat Stemmer-Rachamimov; Daniel P Cahill; Priscilla K Brastianos; Samuel D Rabkin; Robert L Martuza; Hiroaki Wakimoto
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

7.  Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.

Authors:  Nusrat Jahan; Jae M Lee; Khalid Shah; Hiroaki Wakimoto
Journal:  Int J Cancer       Date:  2017-07-19       Impact factor: 7.396

8.  Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.

Authors:  Rutger K Balvers; Anne Kleijn; Jenneke J Kloezeman; Pim J French; Andreas Kremer; Martin J van den Bent; Clemens M F Dirven; Sieger Leenstra; Martine L M Lamfers
Journal:  Neuro Oncol       Date:  2013-09-17       Impact factor: 12.300

9.  Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Authors:  Franz J Zemp; Xueqing Lun; Brienne A McKenzie; Hongyuan Zhou; Lori Maxwell; Beichen Sun; John J P Kelly; Owen Stechishin; Artee Luchman; Samuel Weiss; J Gregory Cairncross; Mark G Hamilton; Brian A Rabinovich; Masmudur M Rahman; Mohamed R Mohamed; Sherin Smallwood; Donna L Senger; John Bell; Grant McFadden; Peter A Forsyth
Journal:  Neuro Oncol       Date:  2013-04-12       Impact factor: 12.300

10.  Modelling glioma invasion using 3D bioprinting and scaffold-free 3D culture.

Authors:  Derek M van Pel; Kaori Harada; Dandan Song; Christian C Naus; Wun Chey Sin
Journal:  J Cell Commun Signal       Date:  2018-06-16       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.